Methylglyoxal: possible link between hyperglycaemia and immune suppression?

Trends in Endocrinology and Metabolism

Volumn 20, Issue 7, 2009, Pages 312-317

  Price, Claire L ^a   Knight, Stella C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ARGININE KINASE; B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; DNA; DNA POLYMERASE; GAMMA INTERFERON; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYOXALASE; HEAT SHOCK PROTEIN 27; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; METHYLGLYOXAL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE C; PROTEIN TYROSINE PHOSPHATASE; RAF PROTEIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DNA DAMAGE; ENZYME ACTIVATION; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION RESISTANCE; INFECTION RISK; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; OXIDATIVE STRESS; PYRUVALDEHYDE;

EID: 69849112427     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.03.010     Document Type: Article

References (64)

1. Kalapos M.P. Methylglyoxal in living organisms: chemistry, biochemistry, toxicology and biological implications. Toxicol. Lett. 110 (1999) 145-175
2. Thornalley P.J. Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. Biochem. Soc. Trans. 31 (2003) 1343-1348
3. Pacher P., and Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid. Redox Signal. 7 (2005) 1568-1580
4. Rolo A.P., and Palmeira C.M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol. 212 (2006) 167-178
5. Goh S.Y., and Cooper M.E. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93 (2008) 1143-1152
6. Thornalley P.J. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems - role in ageing and disease. Drug Metabol. Drug Interact. 23 (2008) 125-150
7. McLellan A.C., et al. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin. Sci. (Lond.) 87 (1994) 21-29
8. Lo T.W., et al. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J. Biol. Chem. 269 (1994) 32299-32305
9. Maillard L.C. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C. R. Acad. Sci. 154 (1912) 66-68
10. Nass N., et al. Advanced glycation end products, diabetes and ageing. Z. Gerontol. Geriat. 40 (2007) 349-356
11. Ahmed N., and Thornalley P.J. Advanced glycation endproducts: what is their relevance to diabetic complications?. Diabetes Obes. Metab. 9 (2007) 233-245
12. Ramasamy R., et al. Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann. N. Y. Acad. Sci. 1126 (2008) 7-13
13. Thornalley P.J. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell. Mol. Biol. (Noisy-le-grand) 44 (1998) 1013-1023
14. Kalapos M.P. The tandem of free radicals and methylglyoxal. Chem. Biol. Interact. 171 (2008) 251-271
15. Faure P., et al. Albumin antioxidant capacity is modified by methylglyoxal. Diabetes Metab. 31 (2005) 169-177
16. Kang J.H. Modification and inactivation of human Cu, Zn-superoxide dismutase by methylglyoxal. Mol. Cells 15 (2003) 194-199
17. Di Loreto S., et al. Methylglyoxal causes strong weakening of detoxifying capacity and apoptotic cell death in rat hippocampal neurons. Int. J. Biochem. Cell Biol. 40 (2008) 245-257
18. Newsholme P., et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J. Physiol. 583 (2007) 9-24
19. Martin I., and Grotewiel M.S. Oxidative damage and age-related functional declines. Mech. Ageing Dev. 127 (2006) 411-423
20. Synold T., et al. Advanced glycation end products of DNA: quantification of N2-(1-carboxyethyl)-2G-deoxyguanosine in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Chem. Res. Toxicol. 21 (2008) 2148-2155
21. Bidmon C., et al. Analysis of DNA-bound advanced glycation end-products by LC and mass spectrometry. J. Chromatogr. B 855 (2007) 51-58
22. Seidel W., and Pischetsrieder M. DNA-glycation leads to depurination by the loss of N2-carboxyethylguanine in vitro. Cell. Mol. Biol. (Noisy-le-grand) 44 (1998) 1165-1170
23. Murata-Kamiya N., et al. Mutations induced by glyoxal and methylglyoxal in mammalian cells. Nucleic Acids Symp. Ser. 44 (2000) 3-4
24. Murata-Kamiya N., et al. Methylglyoxal induces G:C to C:G and G:C to T:A transversions in the supF gene on a shuttle vector plasmid replicated in mammalian cells. Mutat. Res. 468 (2000) 173-182
25. Murata-Kamiya N., and Kamiya H. Methylglyoxal, an endogenous aldehyde, crosslinks DNA polymerase and the substrate DNA. Nucleic Acids Res. 29 (2001) 3433-3438
26. Marble A., et al. The nature of the lowered resistance to infection in diabetes mellitus. J. Clin. Invest. 17 (1938) 423-430
27. Benfield T., et al. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia 50 (2007) 549-554
28. Turan H., et al. Frequency, risk factors, and responsible pathogenic microorganisms of asymptomatic bacteriuria in patients with type 2 diabetes mellitus. Jpn. J. Infect. Dis. 61 (2008) 236-238
29. Movahed M.R., et al. Increased prevalence of infectious endocarditis in patients with type II diabetes mellitus. J. Diabetes Complicat. 21 (2007) 403-406
30. Kukreja A., et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109 (2002) 131-140
31. Stalenhoef J., et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur. J. Clin. Microbiol. Infect. Dis. 27 (2008) 97-103
32. Avanzini M.A., et al. IFN-gamma low production capacity in type 1 diabetes mellitus patients at onset of disease. Exp. Clin. Endocrinol. Diabetes 113 (2005) 313-317
33. Faresjo M.K., et al. Diminished IFN-gamma response to diabetes-associated autoantigens in children at diagnosis and during follow up of type 1 diabetes. Diabetes Metab. Res. Rev. 22 (2006) 462-470
34. Halminen M., et al. Cytokine expression in unstimulated PBMC of children with type 1 diabetes and subjects positive for diabetes-associated autoantibodies. Scand. J. Immunol. 53 (2001) 510-513
35. Lohmann T., et al. Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes. Diabetes 51 (2002) 2474-2480
36. Rodacki M., et al. NK cells and type 1 diabetes. Clin. Dev. Immunol. 13 (2006) 101-107
37. Boulbou M.S., et al. Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension. Int. J. Cardiol. 98 (2005) 39-44
38. Glowinska B., et al. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes. Metabolism 54 (2005) 1020-1026
39. Bouma G., et al. An increased MRP8/14 expression and adhesion, but a decreased migration towards proinflammatory chemokines of type 1 diabetes monocytes. Clin. Exp. Immunol. 141 (2005) 509-517
40. Alba-Loureiro T.C., et al. Neutrophil function and metabolism in individuals with diabetes mellitus. Braz. J. Med. Biol. Res. 40 (2007) 1037-1044
41. Glisic-Milosavljevic S., et al. Dynamic changes in CD4+ CD25+(high) T cell apoptosis after the diagnosis of type 1 diabetes. Clin. Exp. Immunol. 150 (2007) 75-82
42. Otton R., et al. Diabetes induces apoptosis in lymphocytes. J. Endocrinol. 182 (2004) 145-156
43. Sudo C., et al. Clinical significance of neutrophil apoptosis in peripheral blood of patients with type 2 diabetes mellitus. Lab. Hematol. 13 (2007) 108-112
44. Sakowicz-Burkiewicz M., et al. Diabetes-induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytes. Immunology 118 (2006) 402-412
45. Rubinstein R., et al. Impaired immune responses in streptozotocin-induced type I diabetes in mice. Involvement of high glucose. Clin. Exp. Immunol. 154 (2008) 235-246
46. Takahashi K., et al. Lowered expressions of the NF-kappaB family members in dendritic cells from NOD mice are associated with a reduced expression of GATA-2. Ann. N. Y. Acad. Sci. 1150 (2008) 59-60
47. Price C.L., et al. Advanced glycation end products modulate the maturation and function of peripheral blood dendritic cells. Diabetes 53 (2004) 1452-1458
48. Cantero A.V., et al. Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis. FASEB J. 21 (2007) 3096-3106
49. Laga M., et al. Methylglyoxal suppresses TNF-alpha-induced NF-kappaB activation by inhibiting NF-kappaB DNA-binding. Biochem. Pharmacol. 74 (2007) 579-589
50. Tergaonkar V. NF[kappa]B pathway: a good signaling paradigm and therapeutic target. Int. J. Biochem. Cell Biol. 38 (2006) 1647-1653
51. Du J., et al. Methylglyoxal downregulates Raf-1 protein through a ubiquitination-mediated mechanism. Int. J. Biochem. Cell Biol. 38 (2006) 1084-1091
52. Riboulet-Chavey A., et al. Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes 55 (2006) 1289-1299
53. Lee J.W., et al. HSP27 regulates cell adhesion and invasion via modulation of focal adhesion kinase and MMP-2 expression. Eur. J. Cell Biol. 87 (2008) 377-387
54. Sakamoto H., et al. Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. J. Biol. Chem. 277 (2002) 45770-45775
55. Padival A.K., et al. Methylglyoxal modifies heat shock protein 27 in glomerular mesangial cells. FEBS Lett. 551 (2003) 113-118
56. Arrigo A.P., et al. Hsp27 (HspB1) and [alpha]B-crystallin (HspB5) as therapeutic targets. FEBS Lett. 581 (2007) 3665-3674
57. Lee H.J., et al. Methylglyoxal can modify GAPDH activity and structure. Ann. N. Y. Acad. Sci. 1043 (2005) 135-145
58. Sirover M.A. New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. J. Cell. Biochem. 95 (2005) 45-52
59. Gallet X., et al. A fast method to predict protein interaction sites from sequences. J. Mol. Biol. 302 (2000) 917-926
60. Zeng J., et al. Evidence for inactivation of cysteine proteases by reactive carbonyls via glycation of active site thiols. Biochem. J. 398 (2006) 197-206
61. Iberg N., and Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J. Biol. Chem. 261 (1986) 13542-13545
62. Copeland R.J., et al. Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. Am. J. Physiol. Endocrinol. Metab. 295 (2008) E17-E28
63. Budhiraja S., and Singh J. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications. Fundam. Clin. Pharmacol. 22 (2008) 231-240
64. Price, C.L. et al. (2009) Methylglyoxal modulates immune responses: relevance to diabetes. J. Cell. Mol. Med., in press [epub ahead of print]